Bispecific antibody · Immune activation, directed at Programmed cell death protein 1 (PDCD1) and Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) · developed by MacroGenics
Lorigerlimab is a tetravalent, hinge-stabilized IgG4 bispecific antibody-like protein that binds both PD-1 and CTLA-4 on tumor-infiltrating lymphocytes. By blocking these two negative checkpoint receptors, it aims to enhance T-cell activation and proliferation. It is being studied in platinum-resistant ovarian, fallopian tube and peritoneal cancers, clear cell adenocarcinomas of gynecologic sites, and endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06730347 | Phase 2 | Platinum-resistant Ovarian Cancer | Recruiting | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clear Cell Adenocarcinoma of CervixClear Cell Adenocarcinoma of Fallopian TubeClear Cell Adenocarcinoma of OvaryClear Cell Adenocarcinoma of PeritoneumClear Cell Adenocarcinoma of UterusClear Cell Adenocarcinoma of VaginaClear Cell Adenocarcinoma of VulvaEndometrial CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-resistant Ovarian CancerPlatinum-Resistant Primary Peritoneal Carcinoma
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →